Hospira Company Profile (NYSE:HSP)

Analyst Ratings

Consensus Ratings for Hospira (NYSE:HSP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Hospira (NYSE:HSP)
Show:
DateFirmActionRatingPrice TargetActions
5/13/2015Deutsche Bank AGReiterated RatingBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2015Goldman Sachs Group Inc.UpgradeSell -> Neutral$51.00 -> $68.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014JPMorgan Chase & Co.Reiterated RatingNeutral$55.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Barclays PLCReiterated RatingEqual Weight$47.00 -> $53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Bank of America Corp.Reiterated RatingNeutral$61.00 -> $62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Raymond James Financial Inc.UpgradeUnderperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2014CIMBInitiated Coverageadd$2.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014Citigroup Inc.Reiterated RatingSell$35.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Hospira (NYSE:HSP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/4/2015        
7/29/2015Q215$0.80$0.85$1.18 billion$1.20 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2015Q115$0.51$0.97$1.08 billion$1.18 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414$0.42$0.53$1.12 billion$1.13 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.53$0.74$1.08 million$1.15 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q214$0.56$0.72$1.05 billion$1.14 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014Q114$0.49$0.60$1.02 billion$1.10 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2014Q413$0.50$0.51$1.06 billion$1.10 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313$0.45$0.51$992.20 million$1,000.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013$0.51$0.55$1.03 billion$1.03 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q1 2013$0.44$0.52$979.33 million$884.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012$0.54$0.55$1.04 billion$1.10 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312$0.45$0.47$987.67 million$994.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012$0.49$0.51ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2012$0.46$0.47ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2012$0.47$0.51ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2011$0.95$0.66ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2011$0.79$0.94ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2011$0.78$0.93ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2011$0.93$0.77ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hospira (NYSE:HSP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Hospira (NYSE:HSP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Hospira (NYSE:HSP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/2/2015Matthew R StoberSVPSell21,833$87.49$1,910,169.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Matthew R StoberSVPSell25,338$87.47$2,216,314.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Thomas E WernerCFOSell1,566$87.35$136,790.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Thomas E WernerCFOSell10,000$61.56$615,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Matthew R StoberSVPSell2,000$61.80$123,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Thomas E WernerCFOSell10,000$60.86$608,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Richard J HoffmanCAOSell21,850$60.32$1,317,992.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Marc J YoskowitzSVPSell11,523$59.93$690,573.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Kenneth F MeyersSVPSell46,250$59.66$2,759,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Thomas E WernerCFOSell10,000$57.73$577,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Thomas E WernerCFOSell10,000$52.74$527,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Thomas E WernerCFOSell10,000$55.13$551,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2014Thomas E WernerCFOSell10,000$51.50$515,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Thomas E WernerCFOSell10,000$50.82$508,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Thomas WernerCFOSell30,000$47.98$1,439,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Connie CurranDirectorSell2,000$47.44$94,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Barbara BowlesDirectorSell2,000$47.77$95,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Richard HoffmanCAOSell15,000$48.07$721,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Brian SmithSVPSell40,000$48.00$1,920,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Matthew StoberSVPSell19,217$42.28$812,494.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Thomas WernerCFOSell20,000$42.53$850,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013Richard J HoffmanCAOSell9,850$39.38$387,893.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Matthew StoberSVPSell4,990$40.12$200,198.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013Sumant RamachandraSVPSell23,702$35.69$845,924.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Hospira (NYSE:HSP)
DateHeadline
05/04/16 01:11 AMPfizer supera previsiones en primer trimestre - Yahoo Finanzas España - Pfizer supera previsiones en primer trimestreYahoo Finanzas EspañaEl laboratorio estadounidense Pfizer (NYSE: PFE - noticias) superó las previsiones en el primer trimestre gracias a la incorporación de la firma especializada Hospira (NYSE: HSP - noticias) , comprada el año pasado y que permitió contrarrestar la baja ...and more »
05/04/16 01:11 AMPfizer earnings rise, boosted by Hospira assets - Yahoo Finance UK - Pfizer earnings rise, boosted by Hospira assetsYahoo Finance UKPfizer (NYSE: PFE - news) reported a jump in first-quarter earnings Tuesday, reflecting a boost from its Hospira (NYSE: HSP - news) acquisition and strong sales for some of its leading drugs. Earnings were $3.0 billion, up 26.9 percent from the year ...and more »
05/03/16 07:33 AMPfizer earnings rise, boosted by Hospira assets -
03/26/16 11:14 AMVolume Leaders of Healthcare Sector: AVEO Pharmaceuticals, (AVEO), AbbVie (ABBV), AEterna Zentaris (AEZS ... - Street Updates - Street UpdatesVolume Leaders of Healthcare Sector: AVEO Pharmaceuticals, (AVEO), AbbVie (ABBV), AEterna Zentaris (AEZS ...Street UpdatesPfizer Inc. (PFE) made a announcement of August 14, 2015 that it was granted approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer ...
03/22/16 01:32 PMPfizer: 30%+ Discount With 4% Yield - Seeking Alpha - Pfizer: 30%+ Discount With 4% YieldSeeking AlphaWe feel Pfizer is stuck in a short-term rut largely due to the effects of its Allergan merger not yet being realized. Merger will serve to enhance Pfizer's top-line growth, create operational efficiency through a business reorganization, provide tax ...and more »
03/17/16 09:52 AMThe Endless GAAP Vs. Non-GAAP Debate: Instead Focus On Cash Flow - Seeking Alpha - The Endless GAAP Vs. Non-GAAP Debate: Instead Focus On Cash FlowSeeking AlphaIf you read FactSet's "Earnings Insight" this weekend (and I highly recommend you read it every weekend), you will see John Butters focused on the "GAAP vs. Non-GAAP" earnings debate, which surfaces a few times of year and is usually used by the bears ...
02/27/16 11:24 AMHospira Announces U.S. Launch of Generic Bivalirudin for Injection - LAKE FOREST, Ill., July 16, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced it had obtained U.S. Food and Drug Administration ...
02/25/16 10:38 PMHospira and Cerner Expand Agreement to Advance Integration of I.V.-EMR Technology - LAKE FOREST, Ill., and KANSAS CITY, Mo., Aug. 25, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and Cerner (NASDAQ: CERN), a global leader in healthcare technology, today ...
02/02/16 09:50 AMPfizer earnings fall on strong dollar, higher expenses -
01/27/16 11:02 AMNovartis profits jump 73% on asset sales -
01/27/16 08:48 AMUPDATE 3-Novartis hires Hospira's $90 mln man to save Alcon - * Head of Alcon eye division replaced with Canadian-born Ball
11/23/15 11:55 AMWhat Pfizer-Allergan means for manufacturing plant in Rocky Mount -
10/29/15 03:54 AMPfizer, Allergan weigh blockbuster merger: reports -
09/30/15 07:58 AMPfizer Updates 2015 Financial Guidance Solely to Include Hospira Operations In Financial Results From September 3, 2015 Through Year-End 2015 - [at noodls] - NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced updates to certain components of its 2015 financial guidance(1) solely to reflect the impact of the recently completed acquisition of Hospira, ...
09/22/15 04:27 PMIndia-based company doesn't want drug used for executions -
09/18/15 12:39 PMAPNewsBreak: Arkansas execution plan may use UK firm's drug -
09/03/15 05:05 PMPfizer Inc. -- Moody's assigns A1 to Pfizer's proposed exchange notes -
09/03/15 04:35 PMPfizer Inc. Commences Exchange Offers for Hospira Notes - [at noodls] - NEW YORK--(BUSINESS WIRE)--Pfizer Inc. ('Pfizer') (NYSE:PFE) announced today that it has commenced offers to exchange any and all validly tendered and accepted notes of the following series issued by Hospira, ...
09/03/15 03:33 PMEx-Hospira CEO Trades Shares for $91 Million Cash in Pfizer Deal -
09/03/15 11:38 AMHOSPIRA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposit -
09/03/15 08:35 AMPfizer Completes Acquisition of Hospira - [at noodls] - Creates a leading Global Established Pharmaceutical (GEP) Business Expected to be immediately accretive to adjusted diluted EPS1 upon closing;$0.10-$0.12 accretion to adjusted diluted EPS expected in first ...
09/02/15 06:03 AMTwo steady stocks among S&P 500 -
08/28/15 08:00 AMS&P 500 picks up ATVI and UAL -
08/27/15 09:54 AMHospira Announces First Installation of Plum 360™ Infusion System With Hospira MedNet™ - [at noodls] - LAKE FOREST, Ill., Aug. 27, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the first installation of the Plum ...
08/21/15 01:56 AMExpert committee BACKS Hospira’s InflectraTM - [at noodls] - Comparable, safety and efficacy of first mAb biosimilar therapy confirmed by TGA and PBAC Melbourne, Australia, Aug. 21, 2015 -The PBAC today recommended that InflectraTM (infliximab),1 the first monoclonal ...
08/20/15 10:16 AMCharleston Area Medical Center Integrates Smart Pump Technology to Advance Patient Safety - [at noodls] - LAKE FOREST, Ill., Aug. 20, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the successful implementation of ...
08/20/15 04:22 AMTGA Approves First Mab Biosimilar - [at noodls] - Hospira's Inflectra™registered in Australia Melbourne, Australia, Aug 20, 2015 - Hospira today announced that Inflectra™ (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered ...

Social

About Hospira

Hospira logoHospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: HSP
  • CUSIP: 44106010
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $90
  • 200 Day Moving Average: $88
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $3.16 EPS
  • Next Year EPS Consensus Estimate: $3.66 EPS
Additional Links:
Hospira (NYSE:HSP) Chart for Saturday, July, 23, 2016